Delving into the Latest Updates on Micar Innovation Micar21 with Synapse

概览

疾病领域	数量

免疫系统疾病	3
神经系统疾病	3
肿瘤	3
内分泌与代谢疾病	2
感染	1

排名前五的药物类型	数量

小分子化药	15

排名前五的靶点	数量

CCR7	1
GlyT2(甘氨酸转运体2)	1

关联

15

项与 Micar Innovation Micar21 相关的药物

MIC-8471

靶点-

作用机制-

在研机构

Micar Innovation Micar21初创企业

原研机构

Micar Innovation Micar21初创企业

在研适应症

寻常痤疮

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

MIC-4578

靶点

GlyT2

作用机制

GlyT2抑制剂

在研机构

Micar Innovation Micar21初创企业

原研机构

Micar Innovation Micar21初创企业

在研适应症

慢性疼痛

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

MIC-8411

靶点-

作用机制-

在研机构

Micar Innovation Micar21初创企业

原研机构

Micar Innovation Micar21初创企业

在研适应症

黄褐斑

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

100 项与 Micar Innovation Micar21 相关的临床结果

登录后查看更多信息

0 项与 Micar Innovation Micar21 相关的专利（医药）

登录后查看更多信息

5

项与 Micar Innovation Micar21 相关的文献（医药）

2021-01-02·Journal of Biomolecular Structure and Dynamics

Discovery of new AKT1 inhibitors by combination of in silico structure based virtual screening approaches and biological evaluations

Letter

作者: Fratev, Filip ; Aguilera, Renato J. ; Sirimulla, Suman ; Gutierrez, Denisse A. ; Damodaran, Chendil ; Tyagi, Ashish

Communicated by Ramaswamy H. Sarma.

bioRxiv

The R346K mutation in the Mu variant of SARS-CoV-2 alter the interactions with monoclonal antibodies from class 2: a free energy of perturbation study

作者: Fratev, Filip

The Mu variant of SARS-CoV-2 has been recently classified as a variant of interest (VOI) by the world health organization (WHO) but limited data are available at the moment.In particular, a special attention was given to the R346K mutation located in the receptor binding domain (RBD).In the current study we performed Free energy of perturbation (FEP) calculations to elucidate it possible impact on a set of neutralizing monoclonal antibodies (mAbs) which have been shown to be strong inhibitors of the most other known COVID-19 variants.Our results show that R346K affects the class 2 antibodies but its effect is not so significant (0.66 kcal/mol); i.e. reduces the binding with RBD about 3 times.An identical value was calculated also in the presence of both class 1 and class 2 antibodies (BD-812/836).Further, a similar reduction in the binding (0.4 kcal/mol) was obtained for BD-821/771 pair of mAbs.For comparison, the addition of K417N mutation, present in the newly registered Mu variant in July 2021 in UK, affected the class 1 mAbs by 1.29 kcal/mol reducing stronger the binding by about 10 times.Thus, the resistance effect of R346K mutation in the Mu variant is possible but not so significant and is due to the addnl. decrease of antibody neutralization based on the reduced binding of class 2 antibodies.

bioRxiv

The SARS-CoV-2 S1 spike protein mutation N501Y alters the protein interactions with both hACE2 and human derived antibody: a free energy of perturbation study

作者: Fratev, Filip

The N501Y mutation in Covid-19 arise many question but a small amount of data are currently available.An urgent understanding of N501Y mechanism of action at mol. level is highly required.Here, we present the preliminary results of our Free energy perturbation (FEP) and Mol. dynamics (MD) calculations for the interaction of the spike S1 receptor binding domain (RBD) with both the ACE2 receptor and an antibody, STE90-C11, derived from COVID-19 patients.The results shown that the S1 RBD-ACE2 interaction was increased whereas those with the STE90-C11 antibody significantly decreased (over about 160 times).This may explain the observed in UK more spread of the virus but also emerge an important question about the possible human immune response and already available vaccines.Indeed, the latter may still act well but our data indicate some possible reduction of their effect.Further studies of N501Y mutation are need.

100 项与 Micar Innovation Micar21 相关的药物交易

登录后查看更多信息

100 项与 Micar Innovation Micar21 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

15

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

MIC-4578 ( GlyT2 )	慢性疼痛更多	临床前
MIC-2231	僵人综合征更多	临床前
MIC-0540	-	临床前
MIC-1720	类风湿关节炎更多	临床前
MIC-6479	胰腺癌更多	临床前